Literature DB >> 32780485

Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual-Targeting HDAC Inhibitors and HDAC Degraders (PROTACs).

Laura Sinatra1, Jan J Bandolik2, Martin Roatsch1,3, Melf Sönnichsen4, Clara T Schoeder5, Alexandra Hamacher2, Andrea Schöler1, Arndt Borkhardt4, Jens Meiler1,5, Sanil Bhatia4, Matthias U Kassack2, Finn K Hansen1,6.   

Abstract

Inhibition of more than one cancer-related pathway by multi-target agents is an emerging approach in modern anticancer drug discovery. Here, based on the well-established synergy between histone deacetylase inhibitors (HDACi) and alkylating agents, we present the discovery of a series of alkylating HDACi using a pharmacophore-linking strategy. For the parallel synthesis of the target compounds, we developed an efficient solid-phase-supported protocol using hydroxamic acids immobilized on resins (HAIRs) as stable and versatile building blocks for the preparation of functionalized HDACi. The most promising compound, 3 n, was significantly more active in apoptosis induction, activation of caspase 3/7, and formation of DNA damage (γ-H2AX) than the sum of the activities of either active principle alone. Furthermore, to demonstrate the utility of our preloaded resins, the HAIR approach was successfully extended to the synthesis of a proof-of-concept proteolysis-targeting chimera (PROTAC), which efficiently degrades histone deacetylases.
© 2020 The Authors. Published by Wiley-VCH GmbH.

Entities:  

Keywords:  DNA damage; PROTAC; histone deacetylase; multi-target drugs; solid-phase synthesis

Year:  2020        PMID: 32780485      PMCID: PMC7756583          DOI: 10.1002/anie.202006725

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  22 in total

Review 1.  Polypharmacology: challenges and opportunities in drug discovery.

Authors:  Andrew Anighoro; Jürgen Bajorath; Giulio Rastelli
Journal:  J Med Chem       Date:  2014-06-25       Impact factor: 7.446

Review 2.  Multitarget Drugs: an Epigenetic Epiphany.

Authors:  A Ganesan
Journal:  ChemMedChem       Date:  2016-02-18       Impact factor: 3.466

Review 3.  Proteolysis targeting chimeras (PROTACs) for epigenetics research.

Authors:  Anja Vogelmann; Dina Robaa; Wolfgang Sippl; Manfred Jung
Journal:  Curr Opin Chem Biol       Date:  2020-03-05       Impact factor: 8.822

Review 4.  PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.

Authors:  Mariell Pettersson; Craig M Crews
Journal:  Drug Discov Today Technol       Date:  2019-02-13

Review 5.  HDACs and HDAC Inhibitors in Cancer Development and Therapy.

Authors:  Yixuan Li; Edward Seto
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

6.  Tubastatin A, an inhibitor of HDAC6, enhances temozolomide‑induced apoptosis and reverses the malignant phenotype of glioblastoma cells.

Authors:  Alejandro Urdiciain; Elena Erausquin; Bárbara Meléndez; Juan A Rey; Miguel A Idoate; Javier S Castresana
Journal:  Int J Oncol       Date:  2019-03-01       Impact factor: 5.650

Review 7.  HDAC family: What are the cancer relevant targets?

Authors:  Olaf Witt; Hedwig E Deubzer; Till Milde; Ina Oehme
Journal:  Cancer Lett       Date:  2008-09-27       Impact factor: 8.679

Review 8.  The many roles of histone deacetylases in development and physiology: implications for disease and therapy.

Authors:  Michael Haberland; Rusty L Montgomery; Eric N Olson
Journal:  Nat Rev Genet       Date:  2009-01       Impact factor: 53.242

9.  Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals.

Authors:  Laura Gatti; Alexandra Sevko; Michelandrea De Cesare; Noemi Arrighetti; Giacomo Manenti; Emilio Ciusani; Paolo Verderio; Chiara M Ciniselli; Denis Cominetti; Nives Carenini; Elisabetta Corna; Nadia Zaffaroni; Monica Rodolfo; Licia Rivoltini; Viktor Umansky; Paola Perego
Journal:  Oncotarget       Date:  2014-06-30

10.  Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual-Targeting HDAC Inhibitors and HDAC Degraders (PROTACs).

Authors:  Laura Sinatra; Jan J Bandolik; Martin Roatsch; Melf Sönnichsen; Clara T Schoeder; Alexandra Hamacher; Andrea Schöler; Arndt Borkhardt; Jens Meiler; Sanil Bhatia; Matthias U Kassack; Finn K Hansen
Journal:  Angew Chem Int Ed Engl       Date:  2020-10-09       Impact factor: 15.336

View more
  9 in total

1.  Comparison of Cellular Target Engagement Methods for the Tubulin Deacetylases Sirt2 and HDAC6: NanoBRET, CETSA, Tubulin Acetylation, and PROTACs.

Authors:  Anja Vogelmann; Manfred Jung; Finn K Hansen; Matthias Schiedel
Journal:  ACS Pharmacol Transl Sci       Date:  2022-01-27

Review 2.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Authors:  Ming He; Chaoguo Cao; Zhihao Ni; Yongbo Liu; Peilu Song; Shuang Hao; Yuna He; Xiuyun Sun; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

Review 3.  Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy.

Authors:  Mengjiao Zhou; Minjian Yuan; Meng Zhang; Chenyi Lei; Omer Aras; Xiaohong Zhang; Feifei An
Journal:  Eur J Med Chem       Date:  2021-09-04       Impact factor: 7.088

Review 4.  Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives.

Authors:  Robert Jenke; Nina Reßing; Finn K Hansen; Achim Aigner; Thomas Büch
Journal:  Cancers (Basel)       Date:  2021-02-05       Impact factor: 6.639

5.  Design, Synthesis, and Biological Evaluation of HDAC Degraders with CRBN E3 Ligase Ligands.

Authors:  Yingxin Lu; Danwen Sun; Donghuai Xiao; Yingying Shao; Mingbo Su; Yubo Zhou; Jia Li; Shulei Zhu; Wei Lu
Journal:  Molecules       Date:  2021-11-29       Impact factor: 4.411

Review 6.  HDAC Inhibitors: Innovative Strategies for Their Design and Applications.

Authors:  Mateusz Daśko; Beatriz de Pascual-Teresa; Irene Ortín; Ana Ramos
Journal:  Molecules       Date:  2022-01-21       Impact factor: 4.411

Review 7.  Proteolysis-targeting chimeras (PROTACs) in cancer therapy.

Authors:  Xinyi Li; Wenchen Pu; Qingquan Zheng; Min Ai; Song Chen; Yong Peng
Journal:  Mol Cancer       Date:  2022-04-11       Impact factor: 27.401

8.  Chemo-proteomics exploration of HDAC degradability by small molecule degraders.

Authors:  Yuan Xiong; Katherine A Donovan; Nicholas A Eleuteri; Nadia Kirmani; Hong Yue; Anthony Razov; Noah M Krupnick; Radosław P Nowak; Eric S Fischer
Journal:  Cell Chem Biol       Date:  2021-07-26       Impact factor: 9.039

9.  Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual-Targeting HDAC Inhibitors and HDAC Degraders (PROTACs).

Authors:  Laura Sinatra; Jan J Bandolik; Martin Roatsch; Melf Sönnichsen; Clara T Schoeder; Alexandra Hamacher; Andrea Schöler; Arndt Borkhardt; Jens Meiler; Sanil Bhatia; Matthias U Kassack; Finn K Hansen
Journal:  Angew Chem Int Ed Engl       Date:  2020-10-09       Impact factor: 15.336

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.